Next Generation

Immuno-Oncology Therapeutics

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.

>> More about immuno-oncology



Clinical Development in Two Indications

Our lead immuno-oncology candidate asunercept is in clinical development for the treatment of solid tumors and malignant hematological diseases. It has shown significant improvements in progression-free survival and quality of life as well as a positive trend in overall survival in a controlled phase II proof-of-concept trial in recurrent glioblastoma. In a phase I trial in myelodysplastic syndromes (MDS), treatment with asunercept led to a decrease in transfusion frquency in 40 percent of patients during the duration of the trial.



The Apogenix team has created the HERA-ligand technology platform for the development of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology.



December 5, 2019
Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

November 7, 2019
Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology